Trials / Completed
CompletedNCT01984788
Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
A Phase 2a Double-Blind Placebo-Controlled 2-Period Crossover Study to Evaluate the Safety and Efficacy of BCX4161 as a Prophylactic Treatment to Reduce the Frequency of Attacks in Subjects With Hereditary Angioedema
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- BioCryst Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether BCX4161 given as a daily oral prophylactic treatment is safe and effective in reducing the number of acute attacks in patients with hereditary angioedema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BCX4161 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2013-11-15
- Last updated
- 2014-08-18
Locations
6 sites across 2 countries: Germany, United Kingdom
Source: ClinicalTrials.gov record NCT01984788. Inclusion in this directory is not an endorsement.